Complete hematological and major molecular response through treatment with low-dose Interferon alpha 2a in high-risk polycythemia vera patient: a case report

Christoph Driessen; Christoph Noppen; Georg Boonen; Juergen Drewe

doi:10.1002/ccr3.4903

Complete hematological and major molecular response through treatment with low-dose Interferon alpha 2a in high-risk polycythemia vera patient: a case report

Clin Case Rep. 2021 Oct 6;9(10):e04903. doi: 10.1002/ccr3.4903. eCollection 2021 Oct.

Authors

Christoph Driessen¹, Christoph Noppen², Georg Boonen³, Juergen Drewe⁴

Affiliations

¹ Deptartment of Oncology & Hematology Kantonsspital St Gallen Switzerland.
² Viollier AG Allschwil Switzerland.
³ Independent Researcher.
⁴ Department of Clinical Pharmacology University Clinic Basel Basel Switzerland.

Abstract

Low-dose interferon-α 2a treatment may be considered as an alternative to cytoreductive therapy with hydroxyurea or regularly dosed interferon in high-risk polycythemia vera patients.

Keywords: interferon; low dose; polycythemia vera.

Publication types

Case Reports